Vuori Kristiina MD — SEC insider filings
SEC reporting owner CIK 1612627. 27 insider filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2020-10-07 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings — 20,443 shares, $299,957 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: purchase of 6,667 shares @ $15.00 ($100,005) in Inhibrx Biosciences, Inc., filed 2024-10-07.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | Director | 7 | 4 legs · 20,443 sh · $299,957 | — | 4 |
| Forian Inc. (FORA) | Director | 6 | — | — | 12 |
| Bionano Genomics, Inc. (BNGO) | Director | 8 | — | — | 8 |
| Inhibrx, Inc. (INBX) | Director | 4 | — | — | 6 |
| Sio Gene Therapies Inc. (SIOX) | Director | 2 | — | — | 2 |
Insider filings — Vuori Kristiina MD
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4/A | Inhibrx Biosciences, Inc. (INBX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Inhibrx Biosciences, Inc. (INBX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Forian Inc. (FORA) | Code (U): 28,757 · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) | EDGAR |
| 2026-05-14 | 4 | Bionano Genomics, Inc. (BNGO) | Grant/award (A): 9,149 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Bionano Genomics, Inc. (BNGO) | Grant/award (A): 2,775 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | Inhibrx Biosciences, Inc. (INBX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | Forian Inc. (FORA) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-10-07 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 6,667 @ $15 | EDGAR |
| 2024-09-12 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 179 @ $15 · Purchase (P): 6,457 @ $15.07 | EDGAR |
| 2024-09-03 | 4 | Inhibrx Biosciences, Inc. (INBX) | Purchase (P): 7,140 @ $14 | EDGAR |
| 2024-06-20 | 4 | Bionano Genomics, Inc. (BNGO) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-30 | 4 | Inhibrx Biosciences, Inc. (INXB) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-05-30 | 4 | Inhibrx, Inc. (INBX) | Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2024-03-28 | 4 | Forian Inc. (FORA) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Bionano Genomics, Inc. (BNGO) | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2023-05-30 | 4 | Inhibrx, Inc. (INBX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-03-24 | 4 | Forian Inc. (FORA) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-07-18 | 4/A | Bionano Genomics, Inc. (BNGO) | Grant/award (A): 44,470 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Bionano Genomics, Inc. (BNGO) | Grant/award (A): 164,422 (derivative) @ $0 | EDGAR |
| 2022-05-26 | 4 | Inhibrx, Inc. (INBX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-04-18 | 4 | Forian Inc. (FORA) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-12-07 | 4 | Inhibrx, Inc. (INBX) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2021-08-19 | 4 | Bionano Genomics, Inc (BNGO) | Grant/award (A): 40,751 (derivative) @ $0 | EDGAR |
| 2021-06-14 | 4 | Bionano Genomics, Inc (BNGO) | Grant/award (A): 7,528 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | Sio Gene Therapies Inc. (SIOX) | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2021-03-09 | 4 | Forian Inc. (FORA) | Grant/award (A): 5,000 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2020-10-07 | 4 | Axovant Gene Therapies Ltd. (AXGT) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1612627 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs